论文部分内容阅读
目的观察硝苯地平联合马来酸依那普利治疗高血压合并慢性肾病的临床效果及预后。方法选取2012年3月至2015年3月于平舆县人民医院接受治疗的80例高血压合并慢性肾病患者作为研究对象,随机将其分为对照组与观察组,每组40例,对照组接受马来酸依那普利治疗,观察组则在此基础上加用硝苯地平方案,比较不同治疗方案对患者治疗效果及预后的影响。结果治疗后,观察组血清肌酐(Scr)、尿素氮(BUN)、尿微量白蛋白(MAU)分别降低至(144.2±31.4)μmol/L、(10.1±3.0)mmol/L、(24.8±6.6)mg/L,明显低于对照组,差异均有统计学意义(P<0.05);观察组降压有效率为95.0%,高于对照组的75.0%,两组比较差异有统计学意义(P<0.05);两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论在高血压合并慢性肾病患者的临床治疗中,采用硝苯地平联合马来酸依那普利方案,可提高降压效果,优化患者肾功能,改善其预后,值得推广。
Objective To observe the clinical effect and prognosis of nifedipine combined with enalapril maleate in the treatment of hypertension and chronic kidney disease. Methods Eighty hypertensive patients with chronic kidney disease treated in Pingyu County People’s Hospital from March 2012 to March 2015 were randomly divided into control group and observation group, 40 cases in each group and control group Enalapril maleate treatment, the observation group is based on the use of nifedipine program, compare the different treatment options on the treatment effect and prognosis. Results After treatment, serum creatinine (Scr), blood urea nitrogen (BUN) and urinary microalbumin (MAU) decreased to (144.2 ± 31.4) μmol / L and ) mg / L, which was significantly lower than that of the control group (P <0.05). The effective rate of hypotension in the observation group was 95.0%, higher than that in the control group (75.0%), the difference was statistically significant P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion In the clinical treatment of patients with hypertension complicated with chronic kidney disease, the combination of nifedipine and enalapril maleate can improve the antihypertensive effect, optimize the renal function and improve the prognosis of patients with renal disease.